MTRI InMed Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—
Margins
Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—
Returns
ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x
Leverage & solvency
Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $4.94M | $4.60M | $4.14M | $1.09M |
| Cost of revenue | — | $3.24M | $3.50M | $2.73M | $545,889 |
| Gross profit | — | $1.71M | $1.10M | $1.40M | $543,546 |
| R&D expense | $3.03M | $2.82M | $3.22M | $3.73M | $7.28M |
| SG&A expense | $6.66M | $5.41M | $5.80M | $5.85M | $6.87M |
| Operating income | — | — | — | -$7.95M | -$18.60M |
| Pretax income | -$11.37M | -$8.69M | -$7.67M | -$7.93M | -$18.60M |
| Income tax | — | — | $7,100 | $13,100 | — |
| Net income | -$12.56M | -$8.16M | -$7.68M | -$7.95M | -$18.60M |
| EBITDA | — | — | — | -$7.75M | -$18.41M |
| EPS (basic) | -3.12 | -8.36 | -20.14 | -3.25 | -33.17 |
| EPS (diluted) | -3.12 | -8.36 | -20.14 | -3.25 | -33.17 |
| Weighted avg. shares (diluted) | 4.16M | 975,895 | 381,053 | 2.45M | 560,829 |
| Balance sheet | |||||
| Cash & equivalents | $2.19M | $10.74M | $6.57M | $8.91M | $6.18M |
| Short-term investments | $39,670 | $43,384 | $43,064 | $44,422 | $44,804 |
| Receivables | — | $465,104 | $352,838 | $260,399 | $88,027 |
| Inventory | — | $961,173 | $1.24M | $1.62M | $2.49M |
| Current assets | $2.68M | $12.87M | $8.69M | $11.33M | $9.60M |
| PP&E, net | $221,037 | $992,199 | $1.25M | $723,426 | $904,252 |
| Intangibles | — | $1.62M | $1.78M | $1.95M | $2.11M |
| Total assets | $3.03M | $15.58M | $11.82M | $14.11M | $12.79M |
| Current liabilities | $1.96M | $1.84M | $1.97M | $2.00M | $3.32M |
| Total liabilities | $1.96M | $2.15M | $2.62M | $2.02M | $3.71M |
| Shareholders' equity | $1.08M | $13.43M | $9.21M | $12.09M | $9.08M |
| Shares outstanding | 5.34M | 2.00M | 445,908 | 3.33M | 650,667 |
| Cash flow statement | |||||
| Operating cash flow | -$8.64M | -$8.10M | -$6.99M | -$7.28M | -$15.58M |
| Capital expenditure | — | — | $9,293 | $160,014 | $39,108 |
| Free cash flow | — | — | -$7.00M | -$7.44M | -$15.62M |
| Investing cash flow | — | — | -$9,293 | -$661,804 | -$672,999 |
| Financing cash flow | $94,496 | $12.27M | $4.65M | $10.68M | $15.07M |
| Depreciation & amortization | $205,271 | $212,839 | $219,600 | $202,249 | $185,657 |
| Stock-based compensation | $106,866 | $119,307 | $137,714 | $278,155 | $697,894 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.